Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone Deficiency
NCT02976675 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 600
Last updated 2017-06-16
Summary
To evaluate the safety and efficacy of PEG Somatropin Injection in the treatment of children with growth hormone deficiency, as well as to study the feasibility of extending the dosing intervals (once per two weeks) of PEG Somatropin Injection.
Conditions
- Growth Hormone Deficiency
Interventions
- BIOLOGICAL
-
PEG-somatropin
Pegylated somatropin, injection, 54IU/9.0mg/1.0ml/bottle Group of dosing per week:0.20 mg /kg/w, once per week for 26 weeks
- BIOLOGICAL
-
PEG-somatropin
Pegylated somatropin, injection, 54IU/9.0mg/1.0ml/bottle Group of dosing per two weeks:0.20 mg /kg/2w,once per two weeks for 26 weeks
Sponsors & Collaborators
-
Children's Hospital of Fudan University
collaborator OTHER -
Suzhou Municipal Hospital
collaborator OTHER -
General Hospital of Ningxia Medical University
collaborator OTHER -
The First Affiliated Hospital of Henan University of Science and Technology
collaborator OTHER -
Maternal and Child Health Hospital of Hubei Province
collaborator OTHER -
Nantong University
collaborator OTHER -
Changchun GeneScience Pharmaceutical Co., Ltd.
lead INDUSTRY
Principal Investigators
-
Feihong Luo, Doctor · Children's Hospital of Fudan University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 3 Years
- Max Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2015-01-31
- Primary Completion
- 2017-06-30
Countries
- China
Study Locations
More Related Trials
-
Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat SGA Children With Short Stature
NCT02375620 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Extension Study of Pegylated Somatropin to Treat Growth Retardation Caused by Endogenous Growth Hormone Deficiency in Children
NCT03290235 ·Status: UNKNOWN ·Phase: PHASE4
-
A Study to Investigate the Safety and Efficacy of Once-weekly PEG-somatropin (GenSci004) in Children With Growth Hormone Deficiency
NCT06024967 ·Status: UNKNOWN ·Phase: PHASE3
-
Crossover Study to Assess the Safety and Pharmacokinetic of Pegylated Somatropin(PEG Somatropin) in GHD Children
NCT01613573 ·Status: COMPLETED ·Phase: PHASE1
-
Clinical Study of Pegylated Somatropin to Treat Children Growth Hormone Deficiency
NCT02908958 ·Status: UNKNOWN ·Phase: PHASE4
-
A Study Extension Period of PEG-somatropin (Pegylated-somatropin) in the Treatment of Children With Idiopathic Short Stature
NCT03255694 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
A Study of PEG-somatropin Injection to Treat Children of Turner Syndrome
NCT03189160 ·Status: UNKNOWN ·Phase: PHASE2
-
A Study to Investigate Efficacy and Safety of Weekly PEG-somatropin (GenSci004) in Treatment Naive Children With Growth Hormone Deficiency
NCT06007417 ·Status: UNKNOWN ·Phase: PHASE3
-
Safety and Efficacy Phase 3 Study of Long-acting hGH (MOD-4023) in Growth Hormone Deficient Children
NCT02968004 ·Status: COMPLETED ·Phase: PHASE3
-
A Bioequivalence Study of Two Different PEG-rhGH Preparations
NCT06797505 ·Status: COMPLETED ·Phase: PHASE1
-
A Bioequivalence Study of Two Different PEG-rhGH Preparations.
NCT06331026 ·Status: COMPLETED ·Phase: PHASE1
-
The Efficacy and Safety of PEGylated GH for the Treatment of Short Stature in Chinese Children-GLOBE Reg
NCT06037473 ·Status: RECRUITING
-
Safety and Efficacy of Y-shape Pegylated Somatropin in Growth Hormone Deficiency Children
NCT04513171 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Clinical Trial to Compare Pharmacokinetics of Two Different PEG-rhGH Preparations
NCT06135155 ·Status: COMPLETED ·Phase: PHASE1
-
Treatment of Children With Insufficient Secretion of Growth Hormone
NCT00271518 ·Status: UNKNOWN ·Phase: PHASE3
-
A Phase II Study of PEG-rhGH Injection for Short Children Born Small for Gestational Age: Efficacy, Safety, and Pharmacokinetics
NCT07260500 ·Status: RECRUITING ·Phase: PHASE2
-
A Clinical Trail to Compare Pharmacokinetics of Two PEG-rhGH Injections With Different Preparations
NCT06135168 ·Status: COMPLETED ·Phase: PHASE1
-
The Efficacy and Safety of Inpegsomatropin Injection in Children With Short Stature Born Small for Gestational Age
NCT07309562 ·Status: RECRUITING ·Phase: PHASE3
-
A Study of PEG-somatropin in the Treatment of Children With Idiopathic Short Stature
NCT03221088 ·Status: UNKNOWN ·Phase: PHASE2
-
Long-term Efficacy and Safety Evaluation of Growth Hormone in Children in China(CGLS)
NCT06110910 ·Status: RECRUITING
-
Investigating Efficacy and Safety of Once-weekly NNC0195-0092 Treatment Compared to Daily Growth Hormone Treatment (Norditropin® FlexPro®) in Growth Hormone Treatment naïve Pre-pubertal Children With Growth Hormone Deficiency
NCT02616562 ·Status: COMPLETED ·Phase: PHASE2
-
A Study (Phase 1b/2) of GS3-007a Oral Treatment in Children With Growth Hormone Deficiency (PGHD)
NCT07264595 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1/PHASE2
-
A Bioequivalence Study of Two Different Processes of PEG-rhGH Preparations
NCT06840691 ·Status: NOT_YET_RECRUITING ·Phase: PHASE1
-
A Research Study in Chinese Children With a Low Level of Hormone to Grow. Treatment is Somapacitan Once a Week Compared to Norditropin® Once a Day.
NCT04970654 ·Status: COMPLETED ·Phase: PHASE3
-
A Non-inferiority Phase 2 Study to Evaluate the Safety and Efficacy of PEG-rhGH in the Treatment of AGHD
NCT03104010 ·Status: UNKNOWN ·Phase: PHASE2